The Triple Marker Test is a prenatal screening test performed during the second trimester of pregnancy. It measures three specific substances in the mother’s blood to assess the risk of chromosomal abnormalities and neural tube defects in the fetus.
Purpose of the Test:
•Screen for chromosomal abnormalities: Assesses the risk of conditions like Down syndrome (Trisomy 21) and Edwards syndrome (Trisomy 18).
•Detect neural tube defects: Identifies potential issues like spina bifida or anencephaly.
•Evaluate pregnancy health: Provides insights into fetal development and placental function.
Components of the Test:
1.Alpha-Fetoprotein (AFP): A protein produced by the fetus; high levels can indicate neural tube defects, while low levels may suggest chromosomal issues.
2.Human Chorionic Gonadotropin (hCG): A hormone produced by the placenta; abnormal levels can indicate chromosomal abnormalities.
3.Unconjugated Estriol (uE3): A hormone produced by the placenta and fetal liver; low levels may indicate chromosomal or placental problems.
Key Notes:
•Performed between 15 to 20 weeks of pregnancy as part of second-trimester screening.
•It is a risk assessment test, not a diagnostic test. Further testing may be recommended if the results show high risk.
•Often combined with other tests or ultrasounds for more accurate results.
Reviews
There are no reviews yet.